سعر ستاتيروز 20مجم 10 اقراص 2025

Statirose 20 mg tablets, pack of 10 (October Pharma / Pharmagin, Egypt): rosuvastatin, an HMG-CoA reductase inhibitor (statin) for lipid lowering and cardiovascular risk reduction.

• To reduce the risk of major adverse cardiovascular events in adults at increased risk.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolaemia, to slow atherosclerosis progression, and in heterozygous (>=8 years) and homozygous (>=7 years) familial hypercholesterolaemia.Population: Adults and children (familial hypercholesterolaemia)DailyMed (U.S. National Library of Medicine)
• Adjunct to diet in adults with primary dysbetalipoproteinaemia or hypertriglyceridaemia.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most frequent (>=2%): headache, nausea, myalgia, asthenia, constipation.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Acute liver failure or decompensated cirrhosis.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity to rosuvastatin or any excipient.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Myopathy and rhabdomyolysis: risk increases with age >=65, uncontrolled hypothyroidism, renal impairment, interacting drugs, higher dose and Asian ancestry; discontinue if CK markedly elevated or myopathy suspected.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Immune-mediated necrotising myopathy reported rarely; discontinue if suspected.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hepatic dysfunction: transaminase increases; rare fatal and non-fatal hepatic failure.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• CYP2C9/transporter (OATP1B1, BCRP) inhibitors, e.g. ciclosporin, some antivirals, gemfibrozilIncrease rosuvastatin levels and risk of myopathy/rhabdomyolysis; follow label dose limits or avoid.DailyMed (U.S. National Library of Medicine)
• Aluminium/magnesium hydroxide antacidsGive rosuvastatin at least 2 hours before the antacid.DailyMed (U.S. National Library of Medicine)
• WarfarinObtain INR before starting and monitor frequently until stable.DailyMed (U.S. National Library of Medicine)

• Discontinue when pregnancy is recognised (or consider ongoing therapeutic needs); may cause fetal harm based on mechanism; observational data on statins have not identified an increased risk of major malformations.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Present in human milk (limited data); breastfeeding is not recommended during treatment.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Rosuvastatin: Selective competitive inhibitor of HMG-CoA reductase, reducing hepatic cholesterol synthesis and increasing hepatic LDL receptors.